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Abstract
Background: Different classes of antidepressant drugs are used as a treatment for depression by
activating the catecholinergic system. In addition, depression has been associated with decrease of
growth factors, which causes insufficient axonal sprouting and reduced neuronal damage repair. In
this study, antidepressant treatments are analyzed in a cell culture system, to study the modulation
of growth factors.
Results: We quantified the transcription of several growth factors in three cell lines after
application of antidepressant drugs by real time polymerase chain reaction. Antidepressant drugs
counteracted against phorbolester-induced deregulation of growth factors in PMA-differentiated
neuronal SY5Y cells. We also found indications in a pilot experiment that magnetic stimulation
could possibly modify BDNF in the cell culture system.
Conclusion: The antidepressant effects antidepressant drugs might be explained by selective
modulation of growth factors, which subsequently affects neuronal plasticity.
Background
The mechanism of action of antidepressant drugs is far
from well understood. The "catecholamine deficiency
hypothesis" stated that affective disorders like depression
originate in pathologic reduction of catecholamine levels
in the brain [1].
The beneficial effects of antidepression treatment on sero-
tonin and dopamine turnover and the associated recep-
tors start a few weeks after onset of therapy, casting doubt
on a simple mode of action, which should be effective
much faster. Other classes of psychotrophic drugs, like
benzodiazepine, which interact with neurotransmitter
receptors too, become effective within minutes after drug
administration. The mechanism of therapeutic latency of
antidepressant and neuroleptic drugs is not clearly under-
stood. Current hypotheses include slow adaptive proc-
esses after fast access to primary drug targets[2].
Alternatively, it was proposed that antidepressant drugs
alter gene expression or induce nerve plasticity by rear-
ranging neuronal connections [3]. Because the formation
and modification of neuronal connections depend on
nerve activity [4], it appears very likely that drugs trigger
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existing by enhancing exocytosis [5]. Recent work on exo-
and endocytosis revealed profound effects of antidepres-
sant drugs on neurotransmitter secretion and receptor
cycling [6,7]. TGFβ2 occurs in astroglia and various neu-
rons and is known to promote the effects of growth factors
such as NT-3 and 4, GDNF, CNTF and bFGF [8]. Therefore
up-regulation of TGFβ2 and it's secretion via regulated
pathways by PC-12 cells and hippocampus neurons point
towards indirect regulatory roles [9].
In addition to pharmacological treatments, rTMS was first
introduced in 1985 [10] as a non-invasive tool of brain
stimulation. It was proposed that rTMS might be a prom-
ising technique for the therapy of depression [11,12].
However, recent meta analyses and multi-center trials
revealed that rTMS was not as effective as ECT, specifically
for the short term treatment [13,14].
This study focuses mainly on the analysis of growth factor
transcription by real time PCR analysis in a cell culture
system, after administration of antidepressant drugs.
Additionally, morphological effects of antidepressant
treatment were analysed by microscopy and effects of
magnetic stimulation on growth factors were also investi-
gated in preliminary pilot experiments.
We hypothesize that antidepressant drugs rather modu-
late the expression of growth factors than just simply
increase their expression, which in turn stabilize, enhance
or even create neural connections between specific brain
areas, involved in mood regulation.
Results
Antidepressant drugs change transcription of growth 
factors
In this study, we tested the hypothesis that anti-depressive
treatment modulates growth-factor transcription. Antide-
pressants of different classes were administered to SY5Y
Differentiation by PMA and treatment with anti-depressive drugs alter cell morphologyFigu  1
Differentiation by PMA and treatment with anti-depressive drugs alter cell morphology. A. Undifferentiated SY5Y 
cells; B. 10 days treatment with PMA; C. 14 days treatment with PMA and fluoxetine; D. 14 days treatment with PMA and tra-
nylcypromine. Scale bar = 20 µm.Page 2 of 8
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to induce differentiation into neurons [15,16]. Figure 1B
shows that after PMA application for 10 days, most of
SY5Y cells developed long processes, while untreated con-
trols did not (Figure 1A). Administration of fluoxetine
(Figure 1C) and tranylcypromine (Figure 1D) to PMA-
treated SY5Y cells did not induce additional neurite
growth, but led to an increase of intracellular granules.
The effects of magnetic stimulation and antidepressants
on different growth factor transcription were analysed by
rtPCR and were summarized in figure 2. Table 1 shows the
corresponding p-values.
Growth factors became strongly up or down regulated in
PMA-treated SY5Y cells during cultivation. Figures 2 A, B
show that NGF, NT-3, GDNF and BDNF transcription
increased continuously over the 14 day cultivation period
upon PMA treatment, while bFGF, CNTF and Creb
showed a steady decline, but these changes were compen-
satory modulated by antidepressant drugs (Figure 2C–F).
Moreover, the most abundant growth factors like NGF,
GDNF, NT-3 and BDNF, which also showed the strongest
increase, were down-regulated by all four antidepressants
after 14 days of treatment. By contrast, bFGF and CNTF,
which declined upon PMA application, became up-regu-
lated by the drugs, except by amitriptyline. The general
common observation was that all four antidepressant
drugs counteracted alterations of growth factor transcrip-
tion, induced by PMA. The factors, which declined upon
PMA treatment, became up-regulated by antidepressant
drug treatment, while others, which increased were down-
regulated. The results of the significance analysis by Stu-
dent's t-test are displayed in Table 1. It shows that most
changes in growth factor expression were significant with
regard to the corresponding controls, which have been
treated with PMA only.
Repetitive magnetic stimulation (rTMS)
A pilot study was conducted to investigate effects of repet-
itive magnetic stimulation on excitable PC-12 cells. Figure
3A shows that repetitive magnetic stimulation caused an
increase of BDNF, TGFβ2 and tyrosine hydroxylase tran-
scription. Undifferentiated SY5Y cells were also subjected
to repetitive magnetic stimulation for one week. Figure 3B
shows that in contrast to PC-12 cells, where transcription
of BDNF was increased, its transcription decreased in
SY5Y cells. The results were not significantly different in
parametric and non-parametric tests (data not shown),
due to small sample numbers.
Discussion
Because of increasing evidence against the "catecholamine
deficiency hypothesis" to explain patho-mechanism of
depression, an alternative hypothesis on the mechanism
of antidepressants, the "plasticity hypothesis", was pro-
posed [17-19].
In this study we analyzed the transcription of growth fac-
tors in cell culture systems. SY5Y cells were pre-treated by
the phorbolester PMA to induce differentiation into neu-
ronal cells [15,20]. PMA changed transcription levels of
several growth factors massively, but we found that anti-
depressant drugs counteracted these PMA-induced
changes.
Recent post mortem studies in suicide subjects revealed
significantly lower levels of BDNF in the prefrontal cortex
and hippocampus. Authors of several studies provided
evidence that BDNF could be involved in depressive
behaviour [21]. Because growth factors induce the forma-
tion of neurite-like processes [22,23], we concluded from
our microscopic images that the growth factors were also
expressed in SY5Y cells. However, we couldn't confirm the
expression for every factor (data not shown). The mor-
phological changes provide some evidence that the mod-
ulation (up and down regulation) of several growth
factors is responsible for the observed effect. A direct cor-
relation with a single growth factor, like BDNF, can not be
causal [24]. All four classes of antidepressants, tested in
our study, antagonistically reversed strong up or down
regulation of growth factors, induced by PMA in cultured
SY5Y cells [15,20].
The up-regulation of BDNF and Creb in vivo seem to be a
central part of the antidepressant properties of antidepres-
sants [17,19,25], however, there is few evidence for the
variation of other growth factors so far. Different modes of
stress can induce either selective up and down regulation
of BDNF splice variants [26] Earlier gene transcription
studies in in vivo systems had shown that several genes
were either up- or down-regulated by antidepressant treat-
ment [27,28]. These and our observations assign a role of
modulators to antidepressants, rather than pure stimula-
tors of growth factor transcription.
We found that if transcription of a factor increased during
the cultivation period, this increase was attenuated by
antidepressants. On the other hand, antidepressants
increased the transcription of factors that became down
regulated upon PMA-treatment. The antagonistic regula-
tion of growth factors was a common property of all anti-
depressant classes; however, there were differences in
kinetics and specificity. Amitriptyline, for example, did
not prevent the PMA-induced decrease of bFGF and
CNTF, but it worked antagonistically for all other factors.
In general, it favoured more down regulation than other
drugs. Reboxetine worked in an exactly opposite way on
the transcription of growth factors, by strongly increasing
down regulated factors and modestly reducing up regu-Page 3 of 8
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Transcription of growth factors in SY5Y cellsFigure 2
Transcription of growth factors in SY5Y cells. A. Quantification of mRNA in PMA-treated SY5Y cells. Bar legend refers 
to all panels in figure 2; B. magnification of low abundant factors in panel A.; C. Modulation of transcription by amitriptyline; D. 
by fluoxetine; E. by tranylcypromine; F. by reboxetine. Values below 1 indicate antidepressant dependent reduction of growth 
factors.
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classes with similar modulator properties, but with differ-
ent kinetics. Fluoxetine has been shown to increase the
expression of bFGF in rats [29]. This was observed in our
experiments too.
In a pilot experiment PC-12 cells were treated with rTMS.
These cells were chosen, because they are electrical excita-
ble, which made them potentially susceptible for repeti-
tive magnetic stimulation. These cells showed an increase
in BDNF, TGFβ2 and tyrosine hydroxylase (figure 3A). In
contrast to PC-12 cells, SY5Y cells showed a decrease of
BDNF (figure 3B). BDNF mRNA was elevated in all treated
samples, compared to controls; however, statistical signif-
icance was not reached, due to small sample numbers. It
has been shown previously that rTMS and antidepressants
acted in a similar way in rat hippocampus [30] and
humans [31,32]. We could only partly support this
hypothesis.
Conclusion
In summary, we found that antidepressants normalized
PMA-induced growth factor variations and specifically
modulated their expression, depending on the type of the
drug. We conclude from our experiments that antidepres-
sant drugs rather modulate PMA-induced changes of
growth factor transcription, than induce an overall tran-
scription increase. This suggests that a common basic
mechanism of antidepressants normalizes pathologic
deregulation of growth factors, which without treatment
would affect neuronal plasticity.
Methods
Cell culture
Cell lines (PC-12 and SY5Y) were obtained from ECACC,
Salisbury/UK.
PC-12 cells were grown in RPMI 1640 medium while f
cells and SY5Y cells were cultured in Dulbecco's Modifica-
tion of Eagle's medium, supplemented with 10% foetal
calf serum, 100 IU/ml penicillin and 100 mg/ml strepto-
mycin (all reagents from Biochrom, Berlin/Germany) at
37°C in a 5% CO2 humidified incubator. 50 % of the
medium was exchanged every 3 – 4 days. PC-12 cells were
seeded at a density of 40000 per cm2 and SY5Y cells at a
density of 10000 per cm2 in 25 cm2-flasks coated with 8
µg collagen IV per cm2 (Corning Costar, Bodenheim/Ger-
many; Sigma Aldrich, Deisenhofen/Germany) and
allowed to attach for several hours. Cells were collected
after trypsinization and washed 3 times with sterile PBS.
Primary rat hippocampus cells were isolated and cultured
as described earlier [33].
Table 1: Statistical significance analysis
2 days 7 days 14 days 2 days 7 days 14 days
NGF NT-3
Amitryptiline < 0.0001 n.s. n.s. Amitryptiline < 0.0001 n.s. 0.0001
Fluoxetine < 0.0001 n.s. n.s. Fluoxetine < 0.0001 n.s. 0.0017
Tranylcypromine 0.0014 n.s. 0.0032 Tranylcypromine < 0.0001 n.s. 0.0002
Reboxetine < 0.0001 n.s. n.s. Reboxetine 0.0004 0.0027 0.0001
bFGF Leptin
Amitryptiline 0.0012 n.s. < 0.0001 Amitryptiline < 0.0001 < 0.0001 0.0003
Fluoxetine < 0.0001 n.s. < 0.0001 Fluoxetine n.s. < 0.0001 < 0.0001
Tranylcypromine 0.004 < 0.0001 n.s. Tranylcypromine n.s. < 0.0001 < 0.0001
Reboxetine < 0.0001 n.s. < 0.0001 Reboxetine n.s. 0.0021 < 0.0001
CNTF CREB
Amitryptiline n.s. 0.0003 < 0.0001 Amitryptiline n.s. < 0.0001 n.s.
Fluoxetine 0.001 < 0.0001 < 0.0001 Fluoxetine n.s. n.s. n.s.
Tranylcypromine 0.002 < 0.0001 < 0.0001 Tranylcypromine 0.0001 < 0.0001 n.s.
Reboxetine n.s. < 0.0001 < 0.0001 Reboxetine < 0.0001 < 0.0001 0.0002
GDNF -- BDNF
Amitryptiline 0.001 < 0.0001 0.005 Amitryptiline n.s. n.s. 0.002
Fluoxetine < 0.0001 < 0.0001 0.0003 Fluoxetine 0.0005 0.0012 n.s.
Tranylcypromine < 0.0001 n.s. 0.0009 Tranylcypromine n.s. 0.0007 n.s.
Reboxetine n.s. n.s. 0.0006 Reboxetine < 0.0001 n.s. 0.0017
Expressions of growth factors were tested with Student's t-test against the corresponding expression levels at the start of the experiments. 
Expression levels of controls, which were treated for 10 days with PMA, were normalized before testing. The values in the table represent the p-
values, obtained by the t-test. The significance level was set at α = 0.004.Page 5 of 8
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SY5Y cells were incubated with 16 nM PMA (phorbol 12-
myristate 13-acetate) 10 days prior to the experiment.
PMA was always renewed when the medium was changed
and continued to be present during the course of the
experiments. Antidepressant drugs were supplied and
renewed every 3 days. Toxic concentrations were deter-
mined by the MTT-test (methylthiazolydiphenyltetrazo-
lium bromide) [34]. The drugs were applied at
concentration that showed no toxicity in the MTT-test.
The concentrations used: amitriptyline 7 µM, fluoxetine 7
µM, tranylcypromine 100 µM and reboxetine 5 µM. All
experiments were repeated independently at least 8 times
in duplicates.
Repetitive magnetic stimulation
The flasks were paired and transported to the stimulator.
Control cells were placed on a separate table and covered
with a blend. Cells to be stimulated were placed on a pol-
ystyrene block and a round coil was adjusted directly
above. Each treatment consisted of 1000 pulses at an
intensity of 0.63 Tesla at 10 Hz, delivered in 20 trains with
dwell time of 25 seconds. During the procedure the coil
was cooled by ventilation or cooling spray. Afterwards the
cells were immediately returned to the incubator. Cells
were treated every 12 hours and harvested directly after
the 15th treatment.
PC-12 cells were washed twice with PBS prior to trypsin-
detachment, centrifuged (500 g, 5 min, 21°C) and
washed two more times. The pellet was stored at -20°C.
Experiments were repeated two times.
Real-time PCR
mRNA was extracted with "SV Total RNA Isolation Sys-
tem" (Promega, Mannheim/Germany) PC-12 cells or
with the "RNeasy Mini Kit" (Qiagen) for SY5Y according
to manufacture's protocol. cDNA was synthesized using
iScript cDNA Synthesis Kit (Biorad, Munich/Germany)
following manufacturer's instructions. Quantitative PCR
was performed with 25 µl reaction mix containing 5 µl
cDNA-dilution, 12.5 µl iQ SYBR Green Supermix (Biorad)
and 1.5 µl of F- and R-primers for PC-12 cells. 12.5 µl iQ
SYBR Green Supermix, 1 µl primer pair, 1 µl cDNA tem-
plate, 10 µl water. For the sequences of the primer pairs
(MWG-Biotech AG, Ebersberg/Germany) see Additional
file 1 'Primer pairs'. PCR-amplification was performed on
iCycler (Biorad) using a three-step standard protocol with
an annealing temperatures of 62°C (human BDNF,
CNTF, NGF and bFGF), 60°C (all rat primers) and 55°C
(human GDNF, NT-3, Leptin and Creb).
All PCR experiments were done in duplicates. β-actin was
used as internal standard and mRNA copies were calcu-
lated by the formula: mRNA = 2-∆CT. ∆CT-values were cal-
culated from differences between the respective growth
factors and β-actin.
Data analysis and statistical calculation
For each growth factor, four antidepressants were com-
pared (on day 2, 7, 14) with a control sample. Therefore
we used a method for correction for multiple testing (Bon-
ferroni adjustment for each growth factor. Thus, the sig-
nificance level alpha was set at α = 0.004. All statistical
tests were two-sided. The calculations were performed
with the statistical package SPSS (SPSS Inc., Chicago, Il).
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